Latest news in cancer
Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma
This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory BCMA/TACI positive relapsed and/or refractory...
Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)
This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell...
Clinical trial recruitment for BALL CAR T-Cell therapy
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D)...
Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States
Oricell is developing a number of CAR-T therapies and antibody candidates for solid tumors. In the Phase I trial presented at ASCO, a group of patients with...
China to open borders for patients travelling for medical treatment
China to open its borders for the first time since COVID pandemic outbreak. Borders will open for all types of visa. Check how to obtain medical visa for...
March month is colorectal cancer awareness month
March month if observed as colorectal cancer awareness month. Colorectal cancer is second most deadly cancer on this planet and early diagnosis is required for...
Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy
Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd have entered into a collaborative development programme to develop CAR T Cell therapy for...
New drug for primary bone cancer in children
As per the report published in the Journal of Bone Oncology, researchers from the University of East Anglia’s Norwich Medical School demonstrated, that the...
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today...
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing...
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and...
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, CHINA, February 28, 2023 – JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing,...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.